Skip to main content
Premium Trial:

Request an Annual Quote

Nuclea Files for FDA Approval of Breast Cancer, Prostate Cancer Assays

This article has been updated from a previous version, which incorrectly stated that the company had filed for premarket approval of its assays.

SAN FRANCISCO (GenomeWeb News) – Nuclea Biotechnologies said on Wednesday that has filed premarket IDE filings with the US Food and Drug Administration for its breast cancer and prostate cancer assays.

The submission is for the Pittsfield, Mass.-based firm's serum based fatty acid synthase and USP2a diagnostic assays and outlines the use of FAS as a monitoring tool. The company said it began the filing process in mid-2011.

In October Nuclea raised $6.4 million to support its FDA submission for the assays, as well as facility upgrades, new hires, and general operations.

Nuclea develops gene- and protein-based diagnostic tests for the prognosis of disease outcome and for the prediction of therapeutic response. Its three businesses are Nuclea Diagnostic Laboratories, Nuclea Biomarkers, and Nuclea Biotherapeutics. Each operate as wholly owned subsidiaries.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.